Hollis-Eden Pharmaceuticals Updates Upcoming Investor Conference Presentations and Webcasts
07 Noviembre 2008 - 6:00AM
Business Wire
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced
that it has scheduled the following investor conference
presentations and webcasts: Rodman and Renshaw Annual Global
Investment Conference in New York City on November 10, 2008, at
10:20 a.m. Eastern (note change in time from original
announcement). Lazard Capital Markets 5th Annual Healthcare
Conference in New York City on November 18, 2008, at 1:40 p.m.
Eastern. A live webcast will be available from each of these
conferences, and may be accessed under �Event Calendar� on the
Investors section of Hollis-Eden�s website at www.holliseden.com.
The webcasts will be archived at the Company�s website for 30 days.
Richard Hollis, Chairman and CEO of Hollis-Eden, will be delivering
the presentations. About Hollis-Eden Pharmaceuticals, Inc.
Hollis-Eden Pharmaceuticals, Inc. is a world leader in the
development of a proprietary class of adrenal steroid hormones as
novel pharmaceuticals for human health. Through its Hormonal
Signaling Technology Platform, Hollis-Eden is developing a new
series of small molecule compounds that are metabolites or
synthetic analogs of endogenous hormones derived by the adrenal
glands from the body�s most abundant circulating adrenal steroid.
These steroid hormones, designed to restore the biological activity
of cellular signaling pathways disrupted by disease and aging, have
been demonstrated in humans to possess several properties with
potential therapeutic benefit -- they regulate innate and adaptive
immunity, reduce nonproductive inflammation and stimulate cell
proliferation. The Company�s clinical drug development candidates
include TRIOLEX� (HE3286), a next-generation compound currently in
clinical trials for the treatment of type 2 diabetes, ulcerative
colitis and rheumatoid arthritis, and APOPTONE� (HE3235), a
next-generation compound in a clinical trial for late-stage
prostate cancer. In addition to these clinical development
candidates, Hollis-Eden has an active research program that is
generating additional new clinical leads that are being further
evaluated in preclinical models of a number of different diseases.
For more information on Hollis-Eden, visit the Company's website at
www.holliseden.com. This press release contains forward-looking
statements within the meaning of the federal securities laws
concerning, among other things, the potential and prospects of the
Company's drug discovery program and its drug candidates. Any
statement included in this press release that are not a description
of historical facts are forward-looking statements that involve
risks, uncertainties, assumptions and other factors which, if they
do not materialize or prove correct, could cause the Company's
actual results to differ materially from historical results or
those expressed or implied by such forward-looking statements. Such
statements are subject to certain risks and uncertainties inherent
in the Company�s business, including, but not limited to: the
ability to complete preclinical and clinical trials successfully
and within specified timelines, if at all; the ability to obtain
regulatory approval for TRIOLEX (HE3286), APOPTONE (HE3235) or any
other investigational drug candidate; the Company's future capital
needs; the Company's ability to obtain additional funding; the
ability of the Company to protect its intellectual property rights
and to not infringe the intellectual property rights of others; the
development of competitive products by other companies; and other
risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Except as required by law, the Company undertakes no
obligation to update or revise the information contained in this
press release as a result of new information, future events or
circumstances arising after the date of this press release.
Hollis-Eden Pharmaceuticals (MM) (NASDAQ:HEPH)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Hollis-Eden Pharmaceuticals (MM) (NASDAQ:HEPH)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024
Real-Time news about Hollis-Eden Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Más de Hollis-Eden Pharmaceuticals, Inc. Artículos de Noticias